(NewsDirect)
Tryp Therapeutics CEO James Gilligan joinsNatalie Stoberman from the Proactive studio to share how the companyis developing psychedelic-assisted therapy in treating variousdisorders such as binge eating and IBS.
Gilligan says TrypTherapeutics is taking a unique approach with their product, TRP-8803,which is an IV infusion of psilocin, an active metabolite ofpsilocybin. Currently, Gilligan says the company is using oralpsilocybin in their studies while preparing for the use of TRP-8803.Tryp Therapeutics recently secured a $2.4 million private placementthat Gilligan says will allow the company to continue their researchand upcoming clinical trials.
ContactDetails
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.